Adastra Holdings Ltd · CSE:XTRX
Adastra — Investor Presentation (March 2022)
16 slides from Adastra's investor presentation, March 2022
Slide 1: Cannabis Through Art and Science – Investor Presentation
CANNABIS THROUGH ART AND SCIENCE INVESTOR PRESENTATION CSE: XTRX | FRA: D2EP
Slide 2: Disclaimer
DISCLAIMER Investors and prospective investors should rely only on the information contained in the disclosure filings (the “Filings”) of Adastra Holdings Ltd. (the “Company”). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information conta
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS ROBUST SCIENTIFIC CAPABILITIES 1. 13,000 sq.ft. processing facility, combining co-located Chemia Analytics cannabis testing lab and Founded: 2018 Adastra Labs’ extraction systems Langley, BC, 2. Under review by Health Canada for a Dealer’s licence, enabling Adastra to legally p
Slide 4: How We Became a Player in Canadian Cannabis
HOW WE BECAME A PLAYER IN CANADIAN CANNABIS Adastra Labs receives Standard Processing licence Phyto Extractions brand from Health Canada asset acquired PerceiveMD acquired Chemia Analytics receives analytical testing licence Supply agreement Michael Forbes Name changed to Adastra from Heath Canada w
Slide 5: A Platform for Accelerated Growth in Canada
A PLATFORM FOR ACCELERATED GROWTH IN CANADA Trusted global leaders in pharma-quality, development and manufacturing of cannabis API, and derivative products EXTRACT Our extraction methodologies and industry-leading equipment are designed to meet your product development requirements. IMAGE? ANALYZE
Slide 6: Expertise That Differentiates
EXPERTISE THAT DIFFERENTIATES SUPER/SUB SOLVENTLESS DRIED ETHANOL HYDROCARBON FULL SPECTRUM CRITICAL CO2 EXTRACTS FLOWER Extracts Capsules, Tinctures, Capsules, Tinctures, Concentrates, Hash, Rosin, Full Pre Rolls Vapes, Topicals, Vapes, Topicals, Vapes, Shatter, Shatter, Live Spectrum Infused Pre R
Slide 7: One of Canada's Most Popular Concentrates Brands
ONE OF CANADA’S MOST POPULAR CONCENTRATES BRANDS British Columbia’s top selling cannabis concentrates Strong Adastra wholesale sales ▪ $3.3 million from August 2021 to January, 2022 Sept 2021: Purchased 100% of Phyto Extractions brand ▪ Acquired 100% of Phyto Extractions brand1 ▪ Issued 20 million c
Slide 8: Growing Product Portfolio and Availability
GROWING PRODUCT PORTFOLIO AND AVAILABILITY Expanding Distribution with Provincial Wholesalers GROWTH DRIVERS • Introduction of new products, into desired categories AUG 2021 • Retail penetration • New channels • Optimize in-store visibility Available to • Sales force expansion MAY 2020 • Addition of
Slide 9: Adastra Labs
ADASTRA LABS EXTRACTION Adastra Labs is a Health Canada licensed Standard Processor, cannabis product formulator and co-manufacturer, Its 13,000 sq. ft facility is located in Langley, BC, Canada. In 2021, Adastra received its sales licence to sell products directly to provincial distributors. The hy
Slide 10: Chemia Analytics
CHEMIA ANALYTICS IN-HOUSE TESTING LAB Licensed by Health Canada in 2019, Chemia Analytics is Adastra's in-house, co-located testing laboratory. Chemia conducts in-process cannabinoid potency testing, enhancing process efficiency and product quality assurance. It also offers QA/ QC and compliance tes
Slide 11: PerceiveMD
PERCEIVE MD ONE OF BRITISH COLUMBIA’S LEADING MEDICAL CANNABIS AND FORWARD-THINKING THERAPY CLINICS PerceiveMD is a multidisciplinary team-based, patient-focused centre providing free, comprehensive assessments for medical COMPASSIONATE CARE “ Through acquiring PerceiveMD and its extensive team of i
Slide 12: Building Momentum
BUILDING MOMENTUM 190% • Standard Processing licence received, Year-over-year $1.8 1st HALF CO2 processing line commissioned growth 2020 • Vape cartridge sales commence for brands like Phyto Extractions. $1.2 $1.2 • Capacity added to production via 2nd HALF addition of cryo-ethanol extraction 2020 •
Slide 13: Q2 2021 Financial Metrics
Q2 2021 FINANCIAL METRICS Q3 2021 Q3 2020 % Change Revenue $1,808,111 $825,903 119% Cost of sales 874,433 875,485 Gross profit 933,678 49,582 Gross margin 52% -6% Loss from operations (5,703) (3,817,623) Net loss (207,864) (3,895,719) Net loss per share (0.00) (0.10) $1.8 M 119% $0.9 M 52% Revenue Y
Slide 14: Share Count Detail
SHARE COUNT DETAIL Fully Diluted Shares Outstanding Total Shares (as of June 30, 2021) (in millions) Common Shares 65,847,820 Options 2,600,001 (weighted average exercise price of CAD $1.71) Warrants 8,335,992 (weighted average exercise price of CAD $1.80) Compensation Options / Warrants 24,067 Tota
Slide 15: Experienced Leadership Team
EXPERIENCED LEADERSHIP TEAM Michael Forbes Bsc. Pharm, MBA Oliver Foeste CPA, CA CEO & Director CFO ▪ Pharmacist ● Invictus Accounting ▪ Pharmadrug ▪ Ageless Living ▪ Sitka Weed Works ▪ Clarity Cannabis ▪ Honeycomb Cannabis Jean-Paul Lim MD, FRCPC George E. Routhier Paul G. Morgan Chief Strategic Ad
Slide 16: Get In Touch With Us
Get In Touch With Us MICHAEL FORBES,CEO & DIRECTOR michael@adastraholdings.ca +1 (250) 882-3784 CSE: XTRX | FRA: D2EP
Adastra Holdings — Investor Presentation (March 2022) on 6ix